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ABSTRACT 
In this paper we sought to understand what are the effects of cannabinoids on the body and 
how can we enhance the positive effects of cannabinoids while avoiding any negative side 
effects. Previous research has suggested that cannabinoids have numerous physiological effects 
on the body, including effects on the sense of taste, on withdrawal symptoms, and on body mass. 
In this study we measured cannabinoid consumption (g), synthetic THC consumption (mg), and 
compared them to measurements of taste palatability, appetite, and withdrawal symptoms rated 
on subjective scales. Based on pooled standardized data our results supported associations 
between cannabinoids and palatability of sweet tastes, as well as an association between 
synthetic THC consumption and withdrawal symptoms, but no support was found for a reduction 




1.1 Research Problem 
 
With the legalization of cannabinoids 
there has been an overall increase of 
consumption. We are interested in the 
physiological effects on the body of 
consuming cannabinoids and exploring the 
following questions: After consuming 
cannabinoids, can senses of taste, touch, and 
hearing be heightened? What are the effects 
of long-term marijuana usage on the 
physical appearance of the body? Does 
physiological dependence (body withdrawal) 
occur with cannabinoids and is it greater 





1.2 Literature Review 
 
A factor that can predict the effects of 
delta-9-tetrahydrocannabinol (THC) on the 
body is how consumption of THC affects 
appetite to sweet tastes (sucrose) and 
aversive tastes (NaCl). De Luca et al. (2012)  
was used an implant to infuse rats with NaCl 
and sucrose to observe behaviour after THC 
consumption. THC (0.5 or 1.0mg/kg from a 
volume of 20 ml/kg) induced hedonic 
reactions with sucrose (5% and 20%) and 
peaked at 30 minutes as well as having 
significant observations at 60 and 120 
minutes. Palatability of sweet reward was 
found to have significant results, whereas 
the aversive tastes had no effect from THC. 
Taste palatability was measured using 
hedonic valence on a scale of positive, 
negative, and neutral behaviours, which 
were characterised by observing either paw 




licks and various tongue movements or 
gapes, face washing and chin rubs, or 
rhythmic tongue movements, respectively. 
Each of the behaviours was given one point 
if the duration was between one to five 
seconds, and given two points if duration of 
behaviour was greater than five seconds. 
The receptor was discovered to be the 
cannabinoid CB1 receptor. After systemic 
THC consumption, sucrose increased 
dialysate dopamine (DA) in the shell of 
n.accumbens. After repeated exposure the 
effects wore off creating a level of high 
tolerance. De Luca et al. (2012) found this 
was a natural reward and not the same as a 
drug reward and that consumption of THC 
induced palatability of sweets over savery. 
Similarly, previous research on the 
effects of cannabinoids on the body found 
that chronic use of cannabis was associated 
with reduced body mass index( BMI) and 
waistline circumference. In a study by 
Scheffler et al. (2018) researchers studied 
the changes in bmi and fasting blood glucose 
on cannabis users and nonusers who were 
schizophrenic or had a schizo-affective 
disorder and were treated according to a 
standardized treatment regime with depot 
antipsychotic medication over 12 months. 
The study included n=109 participants 
comprising n=40 (37%) Cannabis users and 
n=69 (63%) non users. The participants 
were selected from first-admission to 
psychiatric hospitals and community clinics 
between April 2007 and March 2011 in 
Cape Town. The study found that after a 
period of 12 months, the BMI had 
significantly reduced in participants who 
used cannabis which put them at a lower risk 
for obesity, and in the participants that did 
not use Cannabis, the researchers found that 
there was a significant increase in BMI and 
an elevated waist-line circumference. 
Finally, another effect cannabinoids can 
have on the body is withdrawal after 
consumption. In an experiment by Trexler et 
al. (2020) AB-FUBINACA (0−3 mg/kg, 
i.p.) a member of the indazole carboxamide: 
family of synthetic cannabinoids, was tested 
on adult male and female mice. Their 
response was tested repeatedly measuring 
catalepsy, antinociception, hypothermia, and 
locomotor activity. Experiments were 
carried out by technicians who were blinded 
to the treatment conditions. For the initial 
stage the mice were brought to the test room 
for a minimum of one hour prior to testing, 
to measure: locomotor activity, catalepsy, 
tail immersion, and body temperature. 
Throughout the experiment the mice were 
weighed daily and injected subcutaneously 
(s.c.) with AB-FUBINACA (1 or 3 mg/kg) 
or Placebo- saline, every 12 h for 5 days. On 
the sixth and final day, all mice received 
their final injection of AB-FUBINACA or 
placebo. After 30 min, the mice then 
received an intraperitoneal injection of 
rimonabant (3 mg/kg) a drug given to induce 
withdrawal. The dependent variables 
measured were: incidences of paw tremors 
and head twitches. The results were that 
rimonabant significantly increased both paw 
tremors and head twitches in mice 
repeatedly administered AB-FUBINACA, 
compared to Placebo-treated mice. It is 
noteworthy that, (using these experimental 
procedures) mice administered AB-
FUBINACA alone did not display 
spontaneous somatic withdrawal signs. The 
experiment found that AB-FUBINACA 
(synthetic cannabinoid) produced classic 
cannabimimetic effects, including catalepsy, 
antinociception, hypothermia, and 
hypolocomotion. The study revealed that 
AB-FUBINACA, also produces withdrawal 
effects that diminish much more rapidly than 
the natural cannabinoids. Therefore we can 
infer that the withdrawal effects are more 
significant with use of synthetic 




cannabinoids compared to natural, but also 




Based on the above literature review, we 
predicted the following hypotheses: 
 Hypothesis #1:If cannabinoids 
consumption increases, then taste 
palatability will increase. 
 Hypothesis #2: If cannabinoid 
consumption increases, then appetite will 
decrease. 
 Hypothesis #3: If consumption of 
synthetic THC is increased, then 






The three authors of this paper served as 
the participants in its studies. The 
participants ranged in age from 23 to 29 
years old, with an average age of 25 years, 
and included two females and one male, all 
identifying as cisgender. The participants 
were all undergraduate students at Camosun 
College who completed the current studies 
as an assignment for Psyc 245 (“Drugs and 
Behaviour”) and were grouped together due 
to their mutual interest in Effects of 
Cannabinoids on the physical body. 
Participants have all been consuming 
Cannabinoids regularly for over twelve 
months. 
 
2.2 Materials and Procedure 
 
We performed a correlational study to 
test concurrently all of our hypotheses by 
examining naturalistic daily changes in their 
variables longitudinally. Each participant 
kept a study journal with them at all times 
over this study’s two-week period in order to 
record self-observations of the following 5 
variables: (1) taste palatability, (2) reduced 
appetite (3) withdrawal symptoms, (4) 
cannabinoids consumption, and (5) synthetic 
THC consumption. 
Every day a participant recorded a journal 
for taste palatability and a daily average 
score was calculated regardless of 
cannabinoid consumption across all meals. 
Taste palatability was measured by taste 
enjoyment for sweet (glucose), or savory 
(avserive), and a subjective scale from 1 to 5 
will be used (1 being not enjoyable, and 5 
being very enjoyable) for measuring the 
specific taste palatability each day. If 
cannabinoids were consumed participants 
recorded strain and method of consumption 
before each meal (see below for cannabinoid 
type and route of consumption participants 
may have used). 
To measure reduced appetite (the desire 
to eat food), each participant recorded in 
their study journals the frequency of food 
consumption (how many meals per day) and 
food portions (large, medium, small) each 
day. a subjective scale from one to five (1= 
maintained appetite, 3= moderately reduced 
appetite, 5= extremely reduced) was used to 
record reduced appetite each day. 
Participants measured and recorded an 
average food consumption on days with 
multiple food consumptions, and on days 
with no food consumption the participants 
recorded a score of zero. 
To measure withdrawal symptoms, each 
each participant noted how they felt at the 
beginning of the day and what symptoms of 
withdrawal (if any) they experienced. 
Symptoms were recorded using the Clinical 
Opiate Withdrawal Scale, which measures 
the following symptoms: pulse, sweating, 
restlessness, bone or joint aches, running 
nose or tearing, GI upset, tremor, yawning, 
anxiety and irritability. A clinical 




withdrawal form (see the Appendix) was 
filled out explaining symptoms experienced 
at the beginning of the day before any 
cannabinoids were consumed for that day. A 
scoring system was provided in the 
withdrawal scale: 5-12 = mild; 13-24 = 
moderate; 25-36 = moderately severe; more 
than 36 = severe withdrawal. 
To measure cannabinoid consumption, 
each participant recorded in their study 
journal the type of cannabinoids (sativa, 
indica, hybrid), amount of cannabinoids 
consumed in grams (g), and route of 
consumption (smoke/ joint, pills) each day. 
On days where multiple cannabinoid 
consumption occurred, the participants 
recorded an average of cannabinoid 
consumption, and on days with no 
cannabinoid consumption a score of zero 
was recorded. 
To measure synthetic THC consumption, 
mg of THC in consumed edibles containing 
synthetic THC were measured. Each 
participant recorded the number of edibles 
consumed and the dose of synthetic THC 
that was contained in the product (mg). On 
days where multiple edibles were consumed, 
the participants recorded the number of all 
edible consumptions, and on days with no 
cannabinoid consumption a score of zero 
was recorded. 
To assess the strength and statistical 
significance of associations between 
variables predicted by our three hypotheses, 
we performed Pearson product moment 
correlations of their predictor variables (taste 
palatability, reduced appetite, and 
significance of withdrawal symptoms) with 
their outcome variable (cannabinoids 
consumption and synthetic THC 
consumption). For testing Hypothesis #1, we 
correlated the total amount of cannabinoid 
consumed by each participant each day with 
what the participant's taste palatability was. 
For Hypothesis #2, we correlated the 
consumption of cannabinoids by each 
participant each day with how much food 
the participant consumed. For testing 
Hypothesis #3, we correlated that the use of 
synthetic THC edibles, will result in 
participants experiencing increased 
withdrawal symptoms. We performed all of 
the above correlations separately for each 
participant as well as using data pooled 
across all of the participants. For the 
correlations using pooled data, in addition to 
using the raw data, we also performed 
correlations after we had first transformed 
the data from each participant into z-scores 
in order to standardize differences in 
averages and variability seen between the 
participants in their data and thus make them 
more comparable. A correlation coefficient 
was considered statistically significant if the 
probability of its random occurrence (p) was 
< .05 (i.e., less than 5% of the time expected 




As shown in Table 1, withdrawal 
symptoms, appetite level and palatability to 
savory and sweet were significantly 
correlated with cannabinoid consumption. 
Although not being significant for any single 
participant (all r ≤ 0.53, and all p ≥ 0.05; see 
Table 1), taste palatability for sweets was 
significantly correlated with cannabinoids 
consumed using the pooled standardized 
data (r = 0.46, p = 0.0021; see Figure 1B) 
but not using the pooled raw data (r = 0.19, 
p = 0.224; see Figure 1A). Taste palatability 
for savoury was significantly correlated with 
cannabinoids consumed for Participant #2 (r 
= -0.63, p = 0.015) and Participant #3 (r = 
0.74, p = 0.0015) but not for Participant #1 
(r = 0.08, p = 0.802), where the pooled raw 
data was significant (r = 0.31, p = 0.046; see 
Figure 2A) but the pooled standardized data 




was not significant (r = 0.06, p = 0.689; see 
Figure 2B). 
Withdrawal symptoms were significantly 
correlated with synthetic cannabinoid 
consumption for Participants #1 (r = 0.61, p 
= 0.019) and #3 (r = 0.82, p = 0.0001), but 
not for Participant #2 (r = 0.50, p = 0.069), 
although the significance was seen using 
both the pooled standardized data (r = 0.64, 
p = 1.938E-06; see Figure 3A) and the 
pooled raw data (r = 0.53, p = 0.00019; see 
Figure 3B).  
Testing appetite in relation to 
cannabinoid consumption found significant 
correlations for Participant #2 (r = -0.61, p = 
0.02) and Participant #3 (r = 0.54, p 
=0.047), but not for Participant #1 ( r= 0.17, 
p= 0.56, see Table 1) and not when using 
either the pooled raw data (r = 0.20, p = 
0.19; see Figure 4A) or the standardized 
pooled data (r = 0.03, p = 0.83; see Figure 
4B). 
Based on comparison of the correlation 
coefficients using both pooled raw data and 
standardized pooled data, the withdrawal 
symptoms had the strongest correlation with 
cannabinoid consumption, as well as taste 
palatability for sweets had the second 
strongest correlation with cannabinoid 





4.1 Summary of Results 
 
Of the three tested hypotheses, our results 
found the strongest correlation for 
cannabinoid consumption was withdrawal 
symptoms. Similarly, the hypothesis that 
taste palatability will increase with 
cannabinoid consumption also found 
positive correlation results. Whereas, for the 
hypothesis that if cannabinoid consumption 
increases then appetite will decrease, we 
found no significant evidence correlating the 
two variables. 
 
4.2 Relation of Results to Past Research 
 
For the hypothesis that if cannabinoids 
consumption increases then taste palatability 
will increase, support was found in our 
correlational study. Our findings fall in line 
with previous research conducted by De 
Luca et al (2012). Where rats were tested for 
their taste palatability based off behaviour 
for sweets (licking of paws and lips; wanting 
more) and savoury (face washing, chin rubs; 
and rejection behaviours) after being 
injected with cannabinoids. De Luca et al. 
(2012) found that after cannabinoid 
consumption, rats preferred sweets over 
savoury. While De Luca et al. (2012) used 
mice as their research participants, while our 
study used human participants who regularly 
consume cannabinoid substances. Our study 
also compared taste palatability for sweets 
and savoury variables with cannabinoid 
consumption to observe separate data for 
each, and found palatability for sweets was 
more desirable than savoury after 
cannabinoid consumption. The findings for 
both De Luca et al. (2012), and our study 
had different research design methods, but 
both had similar findings within the research 
suggesting that taste palatability for sweets 
increases as cannabinoid consumption 
increases. 
For the hypothesis that if consumption of 
synthetic THC is increased then withdrawal 
symptoms will increase, our study found 
that the pooled standardized data and pooled 
raw data both showed significant 
correlations, where withdrawal symptoms 
strongly correlated with synthetic 
cannabinoid consumption. Similarly, the 
initial experiment by Trexler et al. (2020) 
found in mice that withdrawal symptoms are 
more significant with synthetic cannabinoid 




use than with natural cannabinoid 
derivatives. While some details were 
different such as the mice were injected with 
the synthetic THC substance 
subcutaneously, whereas in the human trial 
the synthetic THC was ingested by mouth 
and absorbed through the gastrointestinal 
system. 
For the hypothesis that if cannabinoid 
consumption increases then appetite will 
decrease, we found no significant correlation 
between the relationship of cannabinoid 
consumption and appetite for the pooled 
data and raw pooled data, even though 
Participants #2 and #3 both had significant 
results. Scheffler et al. (2018) had found in 
their study that participants who tested 
positive for cannabis had less of an increase 
in body mass index (BMI), than participants 
who tested negative for cannabis. The 
difference between both studies is that 
Scheffler et al. (2018) had been testing with 
schizophrenia patients who typically suffer 
from obesity and cardiometabolic 
complications and were on antipsychotic 
medication. They also used a larger sample 
size (126 participants) over twelve months 
and recorded BMI, where our study used 
three participants over a two weeks period 
and no BMI was recorded, only appetite. 
Further studies will need to be done in order 
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Taste palatability (Sweet) 
& Cannabinoids consumed 
0.36(14) 0.48(14) 0.53(14) 0.19(42) 0.46(42)* 
Taste palatability (Savory) 
& Cannabinoids consumed 
0.08(14) -0.63(14)* 0.74(14)* 0.31(42)* 0.06(42) 
Withdrawal symptoms & 
Synthetic THC 
consumed 
0.61(14)* 0.50(14) 0.82(14)* 0.53(42)* 0.64(42)* 
Reduced appetite & 
Cannabinoids consumed 
0.17(14) -0.61(14)* 0.54(14)* 0.20(42) 0.03(42) 
* p < .05. 
  





Scatterplot of cannabinoids consumed and taste palatability (sweet) of Pooled raw data (A) and 











Marker color indicates which participants data is from. Red = participant #1, Orange = 
participant #2, yellow = participant #3. Some data may not be visible due to overlapping 
markers. 





Scatterplot of cannabinoids consumed and taste palatability (savory) of Pooled raw data (A) and 










Marker color indicates which participants data is from. Red = participant #1, Orange = participant 
#2, yellow = participant #3. Some data may not be visible due to overlapping markers. 





Scatterplot of synthetic cannabinoids (THC) consumed and withdrawal symptoms of Pooled raw 











Marker color indicates which participants data is from. Red = participant #1, Orange = 
participant #2, yellow = participant #3. Some data may not be visible due to overlapping 
markers. 






A.Scatterplot of cannabis consumed and reduced appetite using raw data (A) and pooled 












Marker color indicates which participants data is from. Red = participant #1, Orange = 












Clinical Opiate Withdrawl Scale 
 
